Sorin Group (BIT:SRN) reported flat sales but strong profit growth for 2011, saying it raised earnings by 48.3% and revealing that the cardiac rhythm management slump has made its way across the pond.
The Italian medical device maker posted net income of €58.0 million (~$75.2 million) on sales of €743.4 million (~$963.4 million) for the year ended Dec. 31, 2011. That compares with profits of €39.1 million (~$50.7 million) on sales of €745.8 million (~$966.5 million) during 2010.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Aastrom Biosciences Inc. (NSDQ:ASTMD) finished treating patients in a Phase 2 clinical trial of its cardiac-repair stem cells.
The milestone clears the way for Aastrom to report six-month interim results of the trial later this year, according to a press release.
In the trial, Aastrom treated 40 patients suffering from dilated cardiomyopathy, a severe form of congestive heart failure in which the heart becomes weakened and enlarged and cannot pump blood efficiently.
ANN ARBOR, Mich. – Aastrom Biosciences (NSDQ:ASTMD), once in danger of being de-listed from the NASDAQ exchange, regained compliance with the exchange’s $1 minimum-share-price requirement.
MassDevice Network
@MassDevice
LinkedIn
YouTube